Imaging in Renal Cell Carcinoma Detection

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Sep 28

PMID 39335784

Authors

Dixon Woon

Shane Qin

Abdullah Al-Khanaty

Marlon Perera

Nathan Lawrentschuk

Affiliations

Soon will be listed here.

Abstract

Introduction: Imaging in renal cell carcinoma (RCC) is a constantly evolving landscape. The incidence of RCC has been rising over the years with the improvement in image quality and sensitivity in imaging modalities resulting in "incidentalomas" being detected. We aim to explore the latest advances in imaging for RCC.

Methods: A literature search was conducted using Medline and Google Scholar, up to May 2024. For each subsection of the manuscript, a separate search was performed using a combination of the following key terms "renal cell carcinoma", "renal mass", "ultrasound", "computed tomography", "magnetic resonance imaging", "18F-Fluorodeoxyglucose PET/CT", "prostate-specific membrane antigen PET/CT", "technetium-99m sestamibi SPECT/CT", "carbonic anhydrase IX", "girentuximab", and "radiomics". Studies that were not in English were excluded. The reference lists of selected manuscripts were checked manually for eligible articles.

Results: The main imaging modalities for RCC currently are ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). Contrast-enhanced US (CEUS) has emerged as an alternative to CT or MRI for the characterisation of renal masses. Furthermore, there has been significant research in molecular imaging in recent years, including FDG PET, PSMA PET/CT, Tc-Sestamibi, and anti-carbonic anhydrase IX monoclonal antibodies/peptides. Radiomics and the use of AI in radiology is a growing area of interest.

Conclusions: There will be significant change in the field of imaging in RCC as molecular imaging becomes increasingly popular, which reflects a shift in management to a more conservative approach, especially for small renal masses (SRMs). There is the hope that the improvement in imaging will result in less unnecessary invasive surgeries or biopsies being performed for benign or indolent renal lesions.

References

Morshid A, Duran E, Choi W, Duran C . A Concise Review of the Multimodality Imaging Features of Renal Cell Carcinoma. Cureus. 2021; 13(2):e13231. PMC: 7946646. DOI: 10.7759/cureus.13231. View

Sidhu P, Cantisani V, Dietrich C, Gilja O, Saftoiu A, Bartels E . The EFSUMB Guidelines and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in Non-Hepatic Applications: Update 2017 (Short Version). Ultraschall Med. 2018; 39(2):154-180. DOI: 10.1055/s-0044-101254. View

Siddaiah M, Krishna S, McInnes M, Quon J, Shabana W, Papadatos D . Is Ultrasound Useful for Further Evaluation of Homogeneously Hyperattenuating Renal Lesions Detected on CT?. AJR Am J Roentgenol. 2017; 209(3):604-610. DOI: 10.2214/AJR.17.17814. View

Rizzo A, Racca M, DallArmellina S, Rescigno P, Banna G, Albano D . The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers (Basel). 2023; 15(2). PMC: 9857064. DOI: 10.3390/cancers15020355. View

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

Baccala A, Sercia L, Li J, Heston W, Zhou M . Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007; 70(2):385-90. DOI: 10.1016/j.urology.2007.03.025. View

Tsili A, Andriotis E, Gkeli M, Krokidis M, Stasinopoulou M, Varkarakis I . The role of imaging in the management of renal masses. Eur J Radiol. 2021; 141:109777. DOI: 10.1016/j.ejrad.2021.109777. View

Young J, Young J, Margolis D, Sauk S, Sayre J, Pantuck A . Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT. Acad Radiol. 2017; 24(10):1226-1232. DOI: 10.1016/j.acra.2017.03.017. View

Esquivel A, Ferrero A, Mileto A, Baffour F, Horst K, Rajiah P . Photon-Counting Detector CT: Key Points Radiologists Should Know. Korean J Radiol. 2022; 23(9):854-865. PMC: 9434736. DOI: 10.3348/kjr.2022.0377. View

10.

Chen S, Lin B, Chen S, Qiu Q, Ruan Z, Chen Z . Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study. Int Braz J Urol. 2023; 49(6):716-731. PMC: 10947621. DOI: 10.1590/S1677-5538.IBJU.2023.0312. View

11.

Wang G, Li L, Wang J, Zang J, Chen J, Xiao Y . Head-to-head comparison of [Ga]Ga-P16-093 and 2-[F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023; 50(5):1499-1509. DOI: 10.1007/s00259-022-06101-3. View

12.

Mouracade P, Chavali J, Kara O, Dagenais J, Maurice M, Nelson R . Imaging strategy and outcome following partial nephrectomy. Urol Oncol. 2017; 35(11):660.e1-660.e8. DOI: 10.1016/j.urolonc.2017.06.052. View

13.

Deniffel D, McAlpine K, Harder F, Jain R, Lawson K, Healy G . Predicting the recurrence risk of renal cell carcinoma after nephrectomy: potential role of CT-radiomics for adjuvant treatment decisions. Eur Radiol. 2023; 33(8):5840-5850. DOI: 10.1007/s00330-023-09551-x. View

14.

Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu J . Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2012; 31(2):187-94. PMC: 5795663. DOI: 10.1200/JCO.2011.41.2445. View

15.

van Oostenbrugge T, Mulders P . Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab. Curr Opin Urol. 2021; 31(3):249-254. DOI: 10.1097/MOU.0000000000000872. View

16.

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I . Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and.... Eur Urol. 2019; 77(4):403-417. DOI: 10.1016/j.eururo.2019.01.049. View

17.

Richard P, Jewett M, Bhatt J, Kachura J, Evans A, Zlotta A . Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. Eur Urol. 2015; 68(6):1007-13. DOI: 10.1016/j.eururo.2015.04.004. View

18.

van Oostenbrugge T, Futterer J, Mulders P . Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review. Kidney Cancer. 2019; 2(2):79-93. PMC: 6364093. DOI: 10.3233/KCA-180028. View

19.

Udovicich C, Callahan J, Bressel M, Ong W, Perera M, Tran B . Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma. Eur Urol Open Sci. 2022; 44:60-68. PMC: 9520507. DOI: 10.1016/j.euros.2022.08.001. View

20.

Verhoeff S, van Es S, Boon E, van Helden E, Angus L, Elias S . Lesion detection by [Zr]Zr-DFO-girentuximab and [F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019; 46(9):1931-1939. PMC: 6647180. DOI: 10.1007/s00259-019-04358-9. View